Boston Scientific

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Boston Scientific 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BSX

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. 

CEO
Michael F. Mahoney
CEOMichael F. Mahoney
Employees
59,000
Employees59,000
Headquarters
Marlborough, Massachusetts
HeadquartersMarlborough, Massachusetts
Founded
1979
Founded1979
Employees
59,000
Employees59,000

BSX Key Statistics

Market cap
66.47B
Market cap66.47B
Price-Earnings ratio
18.05
Price-Earnings ratio18.05
Dividend yield
Dividend yield
Average volume
16.78M
Average volume16.78M
High today
$45.45
High today$45.45
Low today
$43.04
Low today$43.04
Open price
$44.20
Open price$44.20
Volume
6.95M
Volume6.95M
52 Week high
$109.50
52 Week high$109.50
52 Week low
$42.20
52 Week low$42.20

Stock Snapshot

As of today, Boston Scientific(BSX) shares are valued at $44.72. The company's market cap stands at 66.47B, with a P/E ratio of 18.05.

On 2026-07-16, Boston Scientific(BSX) stock moved within a range of $43.04 to $45.45. With shares now at $44.72, the stock is trading +3.9% above its intraday low and -1.6% below the session's peak.

Trading volume for Boston Scientific(BSX) stock has reached 6.95M, versus its average volume of 16.78M.

The stock's 52-week range extends from a low of $42.20 to a high of $109.50.

The stock's 52-week range extends from a low of $42.20 to a high of $109.50.

BSX News

TipRanks 1h
Boston Scientific price target lowered to $62 from $64 at Truist

Truist lowered the firm’s price target on Boston Scientific (BSX) to $62 from $64 and keeps a Buy rating on the shares as part of a broader research note previe...

Investing.com 1d
Boston Scientific stock hits 52-week low at 42.24 USD - Investing.com

...

Boston Scientific stock hits 52-week low at 42.24 USD - Investing.com
Simply Wall St 1d
Boston Scientific Stock Looks Cheap On Earnings While Returns Stay Weak

Boston Scientific stock has fallen sharply over the past year, yet the broader valuation checks still lean cheap, which sets up a clear tension between weak rec...

Boston Scientific Stock Looks Cheap On Earnings While Returns Stay Weak

Analyst ratings

87%

of 31 ratings
Buy
87.1%
Hold
12.9%
Sell
0%

More BSX News

Simply Wall St 5d
How Boston Scientific’s 2026 Guidance Cut and Pump Recall At Boston Scientific Has Changed Its Investment Story

In early July 2026, Boston Scientific voluntarily recalled a single Intera Oncology INTERA 3000 Hepatic Artery Infusion Pump (Class II, Serial Number 20175) in...

How Boston Scientific’s 2026 Guidance Cut and Pump Recall At Boston Scientific Has Changed Its Investment Story
Simply Wall St 6d
Is Boston Scientific Undervalued Following Its Russell Growth Index Removal?

Boston Scientific (BSX) has recently been dropped from several Russell growth benchmarks, a broad index reshuffle that can affect how index funds hold the stock...

Is Boston Scientific Undervalued Following Its Russell Growth Index Removal?

People also own

Based on the portfolios of people who own BSX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.